GlaxoSmithKline CEO Emma Walmsley has reportedly received a pay cut of 14 per cent after the company missed an internal profit target for sales of routine vaccinations against other diseases.
According the pharmaceutical giant’s annual report, Ms Walmsley’s total remuneration for 2020 came in at seven million pounds (€8.2 million).
The cut, according to comments by Non-Executive Director Urs Rohner in the report, partly reflected a missed internal profit target for biopharmaceuticals, mainly due to lockdowns stopping people from receiving routine vaccinations which cut into the CEO’s bonus.
Ms Walmsley was appointed CEO in 2017, and has made great strides in the company’s restructuring efforts, as it works to split its consumer and pharmaceutical businesses.
GlaxoSmithKline has been among the frontrunners in the effort to develop COVID-19 vaccines and treatments, with the company’s offering, which was developed in conjunction with the University of Oxford, having been approved for use in over 50 countries.
Last month, pharmaceutical chiefs came under fire as EU leaders prioritised the acceleration of COVID-19 vaccination rollouts, with pharmaceutical companies being pressed to abide by delivery commitments.
Malta’s maritime sector operators welcome US-Iran deal news, expect oil prices to settle if successful
'If flow of fuel continues on its normal path, the first reaction should be a drop in the price of ...
Conrad Aquilina appointed Financial Services Director at EBO.ai
Conrad Aquilina has over 15 years of senior leadership experience in technology and commercial strategy.
Marie Lou Cassar appointed Regional Hub Leader at Aon
She brings three decades of experience in Malta's financial services sector.
Betconstruct AI, which has a regional office in Malta, appoints new CEO
Betconstruct AI is a technology and service provider for the online and land-based gaming industry.
